Incidence of Premature Discontinuation of Antiplatelet Therapy After Sirolimus-Eluting Stent Implantation

Yo Iwata; Yoshio Kobayashi; Kenichi Fukushima; Hideki Kitahara; Tatsuhiko Asano; Naoki Ishio; Takashi Nakayama; Nakabumi Kuroda; Issei Komuro

doi:10.1253/circj.72.340

Rapid Communication

Incidence of Premature Discontinuation of Antiplatelet Therapy After Sirolimus-Eluting Stent Implantation

Yo Iwata, Yoshio Kobayashi, Kenichi Fukushima, Hideki Kitahara, Tatsuhiko Asano, Naoki Ishio, Takashi Nakayama, Nakabumi Kuroda, Issei Komuro

Author information

Yo Iwata
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Yoshio Kobayashi
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Kenichi Fukushima
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Hideki Kitahara
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Tatsuhiko Asano
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Naoki Ishio
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Takashi Nakayama
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Nakabumi Kuroda
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Issei Komuro
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine

Keywords: Antiplatelet therapy, Drug-eluting stent, Late stent thrombosis

JOURNAL FREE ACCESS

2008 Volume 72 Issue 2 Pages 340-341

DOI https://doi.org/10.1253/circj.72.340

Details

Abstract

Background Antiplatelet therapy in patients with sirolimus-eluting stents (SES) may be stopped because of bleeding or an invasive procedure. Methods and Results In 254 patients with SES, the incidence of discontinuation of antiplatelet therapy and subsequent adverse cardiac events was evaluated. Follow-up was complete for 97.2% of the population and mean follow-up was 15.6±8.9 months. Discontinuation of antiplatelet therapy occurred for 46 patients (18.1%): 1 case of late stent thrombosis (2.2%) occurred 10 days after cessation of therapy because of pulmonary hemorrhage 7 months after SES deployment. Conclusion Discontinuation of antiplatelet therapy in patients with SES is not infrequent. (Circ J 2008; 72: 340 - 341)

Corresponding author

Register with J-STAGE for free!